Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07528157 · ClinicalTrials.gov registry record · NA
Early Brainwave Biomarkers for Personalized Neuromodulation in Treatment-resistant Depression
A NA study, sponsored by Stanford University.
- Not yet
- Registry status
- NA
- Development phase
- 80
- Enrollment target
NCT07528157: Clinical Trial NA study, sponsored by Stanford University.
NCT07528157 is a NA study that has not yet begun recruiting, run by Stanford University. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07528157, a NA study, has not yet begun recruiting, sponsored by Stanford University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
Study Summary
This study tests whether a brain stimulation treatment for depression called intermittent theta burst stimulation (iTBS) can be improved by tailoring it to each individual. A type of brain signal measured with electroencephalography (EEG) after a single pulse of brain stimulation, called an early local TMS-evoked potential (EL-TEP), is used to identify which stimulation settings work best for each participant. The investigators will compare individualized (personalized) iTBS settings to standard (non-personalized) settings and to inactive (sham) stimulation. Participants are adults with treatment-resistant depression.
Interventions
- DEVICE Sham iTBS
- DEVICE Personalized iTBS
- DEVICE Non-Personalized iTBS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07528157
The ClinicalTrials.gov registry entry for NCT07528157 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sham iTBS is the first listed.
NCT07528157 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07528157 about?
NCT07528157 is a clinical study titled "Early Brainwave Biomarkers for Personalized Neuromodulation in Treatment-resistant Depression". This study tests whether a brain stimulation treatment for depression called intermittent theta burst stimulation (iTBS) can be improved by tailoring it to each individual. A type of brain signal measured with electroencephalography (EEG) after a single pulse of brain stimulation, called an early lo...
What is the current status of trial NCT07528157?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2026-06-01. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT07528157?
The interventions under investigation include: Sham iTBS (DEVICE), Personalized iTBS (DEVICE), Non-Personalized iTBS (DEVICE).
Who is sponsoring clinical trial NCT07528157?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.